menu search

Seelos therapeutics to present a poster on sls-005 in alzheimer's disease at neuroscience 2023

-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotroph...

October 27, 2023, 8:11 am

Paxmedica’s research on low dose suramin for autism spectrum disorder accepted for publication

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited...

October 26, 2023, 5:51 pm

Bioxytran gets broad patent coverage on 60+ viruses

Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTR...

October 24, 2023, 12:45 pm

Bristol myers' (bmy) opdivo sc meets kidney cancer study goals

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kid...

October 20, 2023, 6:46 am

Bristol myers's injectable kindey cancer drug found non-inferior to iv form

Bristol Myers Squibb said on Thursday its injectable form of blockbuster cancer drug Opdivo was found to be non-inferior to the approved ...

October 19, 2023, 7:11 am

Leqembi® intravenous infusion (lecanemab) approved for the treatment of alzheimer’s disease in japan

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...

September 25, 2023, 5:02 am

Halozyme: intriguing buy prospect despite this week's pdufa setback

Halozyme Therapeutics, based in San Diego, has developed ENHANZE technology based around its proprietary enzyme, rHuPH20. The enzyme makes it possible...

September 12, 2023, 5:59 pm

A bull market is coming: 3 exceptional growth stocks to buy now and hold for a decade

SoFi Technologies is an all-digital bank with a rapidly growing base of members and deposits. Shockwave Medical makes ...

August 15, 2023, 5:13 am

Global indwelling catheters market poised to reach usd 15.3 billion by 2033: redefining patient care, persistence market research

Indwelling Catheters Market Segmented By Indwelling Urinary Catheters, Indwelling Plural Catheters, Indwelling Peritoneal Catheters, Indwelling Nephro...

August 14, 2023, 6:31 pm

Why is paxmedica (pxmd) stock up today?

Clinical-stage biopharmaceutical firm PaxMedica (NASDAQ: PXMD ) is experiencing a full range of emotions following an initial spike in the market toda...

July 24, 2023, 2:17 pm

Ocrevus challenges briumvi: a closer look at tg therapeutics' position

TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Pha...

July 13, 2023, 5:49 pm

Verve therapeutics gains 20.74% in june as ark funds invest

Verve, which was founded in 2018 and went public in June 2021, is developing gene-editing treatments, delivered through a single, ...

June 30, 2023, 7:21 am

Algernon pharmaceuticals subsidiary completes dmt escalating dose study

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the th...

June 5, 2023, 8:11 am

Bridgebio pharma to present updated data from its bbp-812 canavan disease gene therapy program at the 2023 american society of gene and cell therapy (asgct) annual meeting

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

May 15, 2023, 11:30 am

Bridgebio pharma to present updated data from its bbp-812 canavan disease gene therapy program at the 2023 american society of gene and cell therapy (asgct) annual meeting

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

May 15, 2023, 7:30 am

Algernon pharmaceuticals announces successful dosing of second cohort in phase 1 dmt clinical study

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has completed dosing of the second cohort ...

April 4, 2023, 7:46 am

Algernon pharma says unit completes dosing of first cohort in its phase 1 clinical study of an intravenous formulation of dmt

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort i...

February 16, 2023, 7:59 am

Roche (rhhby) actemra gets fda nod for adults with covid-19

Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVI...

December 22, 2022, 10:33 am

Roche gets full fda approval for covid-19 treatment

Roche Holding AG ROG, -0.50% said late Wednesday that the Food and Drug Administration formally approved its monoclonal antibody for adults who have b...

December 22, 2022, 9:49 am

Bioxytran establishes indian subsidiary in preparation of commercialization

BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company de...

December 14, 2022, 12:00 pm


Search within

Pages Search Results: